Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

BACKGROUND: Systemic sclerosis (SSc) is a clinically heterogeneous, life-threatening disease characterized by fibrosis, microvasculopathy, and autoimmunity. Extensive nonclinical and clinical data implicate B cells in the pathogenesis of SSc. MEDI-551 is an investigational humanized monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiopu, Elena, Chatterjee, Soumya, Hsu, Vivien, Flor, Armando, Cimbora, Daniel, Patra, Kaushik, Yao, Wenliang, Li, Jing, Streicher, Katie, McKeever, Kathleen, White, Barbara, Katz, Eliezer, Drappa, Jorn, Sweeny, Sarah, Herbst, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895815/
https://www.ncbi.nlm.nih.gov/pubmed/27267753
http://dx.doi.org/10.1186/s13075-016-1021-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895815/
https://www.ncbi.nlm.nih.gov/pubmed/27267753
http://dx.doi.org/10.1186/s13075-016-1021-2

Ejemplares similares